- Shapeways to provide 3D printed advanced medical models to
be used for pre-planning surgeries
- Parts printed and expected to be delivered within 24 hours
to meet stringent medical timetables
- Complex 3D printed medical models created for
patient-specific treatment
- 3D printed medical model helped plan life-saving surgery for
eight-month-old
- Less surgery time, reduced hospital stays due to 3D modeling
practice for surgeons
- Innovative medical models offer a complete roadmap for
treatment and surgery
Shapeways, a leading global digital manufacturing platform
driven by proprietary software, has entered into an agreement to
become the exclusive 3D printing manufacturer for Armor Bionics, a
specialist in image segmentation and 3D medical modeling. Under the
terms of the agreement, Shapeways will provide Armor Bionics with
certain complex 3D printer medical models that are expected to
transform procedures used for pre-planning surgeries. The
personalized models are developed from patient CT scans and MRIs,
allowing for diagnosis, treatment, and unparalleled surgical
planning and life-saving procedures. Advantages include
significantly reduced time spent in the operating room, shorter
recovery times for patients, and greater ability of surgeons to
anticipate potential complications during a surgery.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210728005136/en/
3D printed infant heart model
manufactured for Armor Bionics by Shapeways transforms surgical
pre-planning. (Photo: Business Wire)
On April 28, 2021, Shapeways entered into a definitive agreement
with Galileo Acquisition Corp. (NYSE: GLEO), a special purpose
acquisition company, related to a proposed business combination
between Galileo and Shapeways. Upon the closing of the transaction,
the combined company will be named Shapeways Holdings, Inc. and is
expected to remain listed on the NYSE under the new ticker symbols
“SHPW” and “SHPW.WS.”
Educating Patients and Empowering Surgeons
With a core strength in industrial design and 3D modeling, Armor
Bionics specializes in developing medical models and offering
biotechnology solutions—with the ultimate goal to make its
technology available to any hospital in the world, whether at a
world-class facility or a small clinic in a developing country.
Bruno Demuro, co-founder and CEO of Armor Bionics, is amplifying
his company’s talents in the area of converting 2D scans to a 3D
design while relying on Shapeways for their manufacturing expertise
and global distribution.
“When we received the first model from Shapeways, it was
absolutely perfect,” said Demuro. “Always being very thorough,
means we measured the size of every bone to find out how accurate
the first 3D printed model was. In comparison to the 3D design we
had sent, it was flawless, which is essential since there is no
room for error in the procedures for which the technique is
used.”
Surgical Pre-Planning Helps Doctors to Prevent
Complications
The critical nature of using 3D printed medical models becomes
even more apparent when surgeons are preparing for delicate
procedures like spinal surgery. Surgeons can make smaller incisions
due to planning on physical models which leads to reduced bleeding
and quicker recovery times. Viewing a physical 3D model of a spine,
heart, or other internal organ allows doctors to plan, adjust, and
practice the surgery beforehand which leads to shorter
surgeries.
Dr. Christian Kreutzer, Chief of Congenital Heart Surgery at
Hospital Universitario Austral and former fellow of Children's
Hospital, Boston and Harvard Medical School, has worked with Armor
Bionics to replicate an eight-month-old patient’s heart. While
viewing the medical model, he adapted the planned surgery which
helped reduce recovery time by half.
“Armor Bionics and Shapeways lets me focus on what I do best,
saving children and improving their lives through surgeries. Their
platform easily converts scans into physical 3D models that are to
scale and guide our approach in surgical pre-planning,” says Dr.
Kreutzer. “Utilizing this technology reduces time in surgery, leads
to quicker recovery times, and produces more positive surgical
outcomes overall.”
Shapeways Provides Global Access
Armor Bionics realized a manufacturing partnership with
Shapeways would also yield the chance to reach many geographical
locations easily. Shapeways’ facilities in the US and Europe help
surgeons get the medical models quickly.
“One of the greatest barriers in expanding our work with even
more surgical teams was the lack of reliable facilities for 3D
printing models once they were sent from Uruguay, where Armor
Bionics is headquartered,” continued Demuro. “By partnering with
Shapeways, surgeons can now receive 3D models anywhere, with
extremely fast delivery and high model accuracy.”
Armor Bionics’ services transforms medical scans into 3D printed
physical models and pairs with Shapeways capabilities for an
innovative solution. “Working hand-in-hand with Armor Bionics
Shapeways developed a way to perform the crucial and difficult task
of converting digital scans into physical form factors that can be
held, manipulated, and even used for hands-on practicing of
procedures,” said Miko Levy, Chief Revenue Officer at Shapeways.
“This revolutionary service offering enables surgeons and hospitals
to get physical models fast, makes surgeries more efficient, and
can assist surgeons in numerous ways to help achieve the best
outcome for their patients.”
The medical models are already being used by surgeons around the
world, and Armor Bionics plans to pursue further expansion in the
US and Europe.
About Shapeways
Shapeways is a leader in the large and fast-growing digital
manufacturing industry combining high quality, flexible on-demand
manufacturing powered by purpose-built proprietary software which
enables customers to rapidly transform digital designs into
physical products, globally. Shapeways makes industrial-grade
additive manufacturing accessible by fully digitizing the
end-to-end manufacturing process, and by providing a broad range of
solutions utilizing 11 additive manufacturing technologies and more
than 90 materials and finishes, with the ability to easily scale
new innovation. Shapeways has delivered over 21 million parts to 1
million customers in over 160 countries.
About Galileo
Galileo Acquisition Corp. raised $138 million in October 2019
and its securities are listed on the New York Stock Exchange under
the ticker symbols “GLEO.U,” “GLEO” and “GLEO.WS.” Galileo is a
blank check company organized for the purpose of effecting a
merger, capital stock exchange, asset acquisition, or other similar
business combination with one or more businesses or entities with
an initial focus on targets operating in the Consumer, Retail, Food
and Beverage, Fashion and Luxury, Specialty Industrial, Technology
or Healthcare sectors which are headquartered in Europe or North
America, and that have a European and North American market nexus.
Galileo is led by a serial SPAC sponsor team having successfully
completed four business combinations, in addition to Shapeways. Its
team is composed by seasoned dealmakers with diverse nationalities,
M&A, principal investing and public company operating
experience in both the North American and Western European
markets.
On June 9, 2021, Galileo filed a registration statement (the
“Registration Statement”) on Form S-4 with the U.S. Securities and
Exchange Commission (“SEC”) that includes a preliminary proxy
statement / prospectus in connection with the proposed business
combination, which is available on the SEC website at
www.sec.gov.
Forward-Looking Statements
Certain statements included in this press release are not
historical facts and are forward-looking statements for purposes of
the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as “believe,”
“may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
“expect,” “should,” “would,” “plan,” “predict,” “potential,”
“seem,” “seek,” “future,” “outlook,” and similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. All statements, other than
statements of present or historical fact included in this press
release, regarding Galileo’s proposed acquisition of Shapeways,
Galileo’s ability to consummate the transaction, the benefits of
the transaction and the combined company’s future financial
performance, market opportunity, as well as the combined company’s
strategy, future operations, estimated financial position,
estimated revenues and losses, projected costs, prospects, plans
and objectives of management are forward-looking statements. These
statements are based on various assumptions, whether or not
identified in this press release, and on the current expectations
of the respective management of Shapeways and Galileo and are not
predictions of actual performance. These forward-looking statements
are provided for illustrative purposes only and are not intended to
serve as, and must not be relied on as, a guarantee, an assurance,
a prediction, or a definitive statement of fact or probability.
Actual events and circumstances are difficult or impossible to
predict and will differ from assumptions. Many actual events and
circumstances are beyond the control of Shapeways and Galileo.
These forward-looking statements are subject to a number of risks
and uncertainties, including changes in domestic and foreign
business, market, financial, political, and legal conditions; the
inability of the parties to successfully or timely consummate the
proposed transaction, including the risk that any regulatory
approvals are not obtained, are delayed or are subject to
unanticipated conditions that could adversely affect the combined
company or the expected benefits of the proposed transaction or
that the approval of the stockholders of Galileo or Shapeways is
not obtained; failure to realize the anticipated benefits of the
proposed transaction; the risk that Shapeways has a history of
losses and may not achieve or maintain profitability in the future;
the risk that Shapeways faces significant competition and expects
to face increasing competition in many aspects of its business,
which could cause our operating results to suffer; the risk that
the digital manufacturing industry is a relatively new and emerging
market and it is uncertain whether it will gain widespread
acceptance; the risk that if Shapeways fails to grow its business
as anticipated, its revenues, gross margin and operating margin
will be adversely affected; the risk that if Shapeways’ new and
existing solutions and software do not achieve sufficient market
acceptance, its financial results and competitive position will
decline; the amount of redemption requests made by Galileo’s
stockholders; the ability of Galileo or Shapeways to issue equity
in connection with the proposed transaction or in the future, and
those factors discussed in Galileo’s Registration Statement, under
the heading “Risk Factors,” and other documents Galileo has filed,
or will file, with the SEC. If any of these risks materialize or
our assumptions prove incorrect, actual results could differ
materially from the results implied by these forward-looking
statements. There may be additional risks that neither Galileo nor
Shapeways presently know, or that Galileo nor Shapeways currently
believe are immaterial, that could also cause actual results to
differ from those contained in the forward-looking statements. In
addition, forward-looking statements reflect Galileo’s and
Shapeways’ expectations, plans, or forecasts of future events and
views as of the date of this press release. Galileo and Shapeways
anticipate that subsequent events and developments will cause
Galileo’s and Shapeways’ assessments to change. However, while
Galileo and Shapeways may elect to update these forward-looking
statements at some point in the future, Galileo and Shapeways
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing Galileo’s and Shapeways’ assessments of any date
subsequent to the date of this transcript. Accordingly, undue
reliance should not be placed upon the forward-looking
statements.
Information Sources; No Representations
The information in the release does not purport to be
all-inclusive. The information therein is derived from various
internal and external sources, with all information relating to the
business, past performance, results of operations and financial
condition of Galileo derived entirely from Galileo and all
information relating to the business, past performance, results of
operations and financial condition of Shapeways derived entirely
from Shapeways. No representation is made as to the reasonableness
of the assumptions made with respect to the information therein, or
to the accuracy or completeness of any projections or modeling or
any other information contained therein. Any data on past
performance or modeling contained therein is not an indication as
to future performance.
No representations or warranties, express or implied, are given
in respect of this release. To the fullest extent permitted by law
in no circumstances will Galileo or Shapeways, or any of their
respective subsidiaries, affiliates, shareholders, representatives,
partners, directors, officers, employees, advisors or agents, be
responsible or liable for any direct, indirect or consequential
loss or loss of profit arising from the use of this release, its
contents, any omissions, reliance on information contained within
it, or on opinions communicated in relation thereto or otherwise
arising in connection therewith, which information relating in any
way to the operations of Shapeways has been derived, directly or
indirectly, exclusively from Shapeways and has not been
independently verified by Galileo.
Additional Information and Where to Find It
In connection with the proposed transaction, Galileo has filed
the Registration Statement with the SEC, which includes a
preliminary proxy statement/prospectus of Galileo, as may be
amended from time to time. Galileo will mail a definitive proxy
statement/prospectus and other relevant documents to its
shareholders.
INVESTORS AND SECURITY HOLDERS OF GALILEO ARE URGED TO READ THE
REGISTRATION STATEMENT ON FORM S-4, WHICH WAS FILED WITH THE SEC ON
JUNE 9, 2021 AND INCLUDES A PRELIMINARY PROXY STATEMENT/PROSPECTUS,
AND, WHEN AVAILABLE, ANY AMENDMENTS THERETO, AND THE DEFINITIVE
PROXY STATEMENT/PROSPECTUS IN CONNECTION WITH GALILEO'S
SOLICITATION OF PROXIES FOR ITS SPECIAL MEETING OF SHAREHOLDERS TO
BE HELD TO APPROVE THE PROPOSED TRANSACTION BECAUSE THE PROXY
STATEMENT/PROSPECTUS CONTAINS AND WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE
PROPOSED TRANSACTION. THE DEFINITIVE PROXY STATEMENT/PROSPECTUS
WILL BE MAILED TO SHAREHOLDERS OF GALILEO AS OF A RECORD DATE TO BE
ESTABLISHED FOR VOTING ON THE PROPOSED TRANSACTION.
Shareholders will also be able to obtain copies of the
Registration Statement, including the proxy statement/prospectus,
the Current Report, and any other documents filed by Galileo with
the SEC, free of charge at the SEC's website (www.sec.gov).
Participants in the Solicitation
Galileo and Shapeways and their respective directors, executive
officers and employees and other persons may be deemed to be
participants in the solicitation of proxies from the holders of
Galileo ordinary shares in respect of the proposed business
combination. Galileo shareholders and other interested persons may
obtain more detailed information regarding the names and interests
in the proposed transaction of Galileo's and Shapeways’ directors
and officers in Galileo’s and Shapeways’ filings with the SEC
including the Registration Statement which includes a preliminary
proxy statement/prospectus of Galileo for the proposed transaction.
These documents can be obtained free of charge from the sources
indicated above.
Disclaimer
This communication shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed business combination. This communication
shall not constitute an offer to sell or the solicitation of an
offer to buy any securities pursuant to the proposed transactions
or otherwise, nor shall there be any sale of securities in any
jurisdiction in which the offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210728005136/en/
Investor Relations investors@shapeways.com
Media Relations press@shapeways.com
Galileo Acquisition (NYSE:GLEO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Galileo Acquisition (NYSE:GLEO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024